The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors
Howard C. Crawford(Henry Ford Health System), Lynn M. Matrisian(Pancreatic Cancer Action Network), Bonnee Rubinfeld, Barbara Fingleton(Vanderbilt University), Laura A. Rudolph‐Owen(Vanderbilt University), Paul Polakis(Intarcia Therapeutics (United States)), Kathleen H. Goss(Vanderbilt University)
Cited by 670
Related Papers
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
|Cancer Research|2014|7.2k
Wnt signaling and cancer
|Genes & Development|2000|3.2k
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
|Science|2002|2.7k
Metalloproteinases and their inhibitors in matrix remodeling
|Trends in Genetics|1990|1.6k
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
|Journal of Clinical Oncology|2000|1.6k